MailMyPrescriptions is a licensed and accredited US Pharmacy with the following Certifications:
Powered by GeniusRx
How does an FSA work?
Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Bimatoprost ophthalmic solution is used topically to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are intolerant of other IOP-lowering drugs or who have not responded adequately (i.e., failed to achieve target IOP as determined after multiple measurements over time) to another IOP-lowering drug. Safety and efficacy of bimatoprost have not been established for the treatment of angle-closure, inflammatory, or neovascular glaucoma.
Safety and efficacy of bimatoprost have been evaluated in 2 multicenter, randomized, double-blind studies that involved several hundred patients with open-angle glaucoma or ocular hypertension. In these studies, which included patients with a mean baseline IOP value of 26 mm Hg, topical application of bimatoprost 0.03% once daily reduced IOP by 7-8 mm Hg. Limited data indicate that bimatoprost 0.03% is at least as effective as latanoprost 0.005% in controlling diurnal IOP. Once daily administration of bimatoprost 0.03% appears to be more effective than twice daily administration of timolol 0.5% in reducing IOP in patients with open-angle glaucoma or ocular hypertension. In one comparative study in patients with mean baseline IOP of 26 mm Hg who received bimatoprost 0.03% once daily or timolol 0.5% twice daily, 64% of those who received bimatoprost had an IOP of less than 17 after 6 months of treatment compared with 37% of those who received timolol when IOP was measured at the time of peak timolol effect.
Dosage and Administration
Bimatoprost is applied topically to the eye as an ophthalmic solution. Care should be taken to avoid contamination of the solution container. (See Advice to Patients.)
If the patient is receiving more than one topical ophthalmic drug, the drugs should be administered at least 5 minutes apart.
The recommended dosage of bimatoprost for the treatment of open-angle glaucoma or ocular hypertension is one drop of a 0.03% solution in the affected eye(s) once daily in the evening. Bimatoprost solution 0.03% should not be administered more frequently than once daily since more frequent dosing may paradoxically diminish the IOP-lowering effect of the drug.
No special population dosage recommendations at this time.
Known hypersensitivity to bimatoprost or any ingredient in the formulation.
Increases in brown pigmentation of the iris and periorbital tissue (eyelid) or increased pigmentation and growth of eyelashes occurred in approximately 2 or 6% of patients, respectively, receiving the drug in clinical studies of up to 12 months' duration; these changes may be permanent. The increased pigmentation of the iris develops slowly and may not be evident until after several months to years of bimatoprost therapy. Long-term effects of these changes are unknown. Pending further accumulation of data, patients receiving bimatoprost should be examined regularly and, depending on the clinical situation, therapy may be discontinued if increased pigmentation persists. Eyelashes may become longer, thicker, more numerous, and darker. Patients expected to receive bimatoprost therapy in only one eye should be informed of the potential for a disparity between eyes in length, thickness, and/or number of eyelashes and that heterochromia between the eyes may occur.
Macular edema, including cystoid macular edema, has been reported during therapy with bimatoprost ophthalmic solution. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema. Use with caution in patients with active intraocular inflammation (e.g., uveitis).
Bimatoprost is distributed in milk in animals. Caution if used in nursing women.
Safety and efficacy not established in children.
No substantial differences in safety and efficacy relative to younger adults.
Renal and Hepatic Impairment
No studies have been performed in these patients; use with caution.
Common Adverse Effects
Conjunctival hyperemia, growth of eyelashes, and ocular pruritus occurred in approximately 15-45% of patients who received bimatoprost ophthalmic solution in clinical trials. Approximately 3% of patients discontinued therapy because of conjunctival hyperemia. Ocular dryness, visual disturbance, ocular burning, foreign body sensation, ocular pain, pigmentation of the periocular skin, blepharitis, cataract, superficial punctate keratitis, eyelid erythema, ocular irritation, and eyelash darkening have been reported in approximately 3-10% of patients who received bimatoprost ophthalmic solution in clinical trials. Adverse ocular effects reported in approximately 1-3% of patients include ocular discharge, tearing, photophobia, allergic conjunctivitis, asthenopia, increases in iris pigmentation, and conjunctival edema.
Adverse systemic events reported in approximately 1-10% of patients include infection (primarily colds and upper respiratory tract infections), headache, abnormal liver function test results, asthenia, and hirsutism.
No formal drug interaction studies have been performed. The manufacturer states that pharmacokinetic interactions are unlikely.
Following once-daily topical ocular administration for 2 weeks, peak blood concentrations were attained within 10 minutes and were below the lower limit of detection within 1.5 hours. Steady-state blood levels were achieved during the first week of dosing.
Reduction in IOP generally occurs within 4 hours after topical application and peaks within 8-12 hours.
Moderately distributed into body tissues with a steady-state volume of distribution of 0.67 L/kg. In human blood, bimatoprost resides mainly in the plasma.
Bimatoprost is distributed into milk in animals; it is not known whether the drug distributes into milk in humans.
Plasma Protein Binding
Undergoes oxidation, N-deethylation, and glucuronidation to form various metabolites.
Approximately 67% excreted in urine and 25% excreted in feces after IV administration.